The Push at FDA to Tighten Oversight on DTC Prescription Drug Ads

In September 2025, President Trump issued a statement pushing FDA to more strictly enforce existing regulations regarding DTC advertising for prescription drugs. At the time, the President’s memo argued that FDA was allowing too little information about the drugs to be included in the advertisements, leading in a rise in these sorts of ads.

HHS Secretary Kennedy has also highlighted his concerns with DTC prescription drug advertisements. At the time of the President’s statement, Secretary Kennedy issued a news release in which he said, ““Pharmaceutical ads hooked this country on prescription drugs. We will shut down that pipeline of deception and require drug companies to disclose all critical safety facts in their advertising. Only radical transparency will break the cycle of overmedicalization that drives America’s chronic disease epidemic.”

Since then, DTC advertisements have remained a talking point among the administration, but very little official action has been taken.

Dan Troy, currently a managing director and expert witness at Berkley Research Group and former lead counsel at FDA under previous administrations, spoke with Pharmaceutical Executive about the issues with regulating DTC advertisements. According to him, it might be harder to restrict these sorts of advertisements, which may not be having the negative impact officials have claimed.

Pharmaceutical Executive: Why is there a push at FDA to increase oversight on DTC prescription drug ads?
Dan Troy: Secretary Kennedy and a number of other people (I guess one would characterize them in the Maha movement) believe that DTC ads over medicalize our society, and that they push people to take medicines that perhaps they shouldn't.

I'm not sure. There's a lot of data behind that view, and in fact, there's a lot of data about the good that DTC ads do. But DTC ads, which can be annoying, let's all acknowledge that, are exceedingly unpopular and are often blamed wrongly for drug prices being too high.

There's a concern about drug ads on television and on social media, because there's a sense that they may not give the full picture of risks. Although, as we all know, there are lots and lots of risks that are disclosed in DTC ads (which is occasionally one of the things that can make them so annoying).

Also, there's a lot of suspicion of social media. Some of it is well warranted, and there's a sense that people are uniquely susceptible to being influenced by social media.